ATE496301T1 - Verfahren zur krebsdiagnose mittels gpc3-nachweis - Google Patents

Verfahren zur krebsdiagnose mittels gpc3-nachweis

Info

Publication number
ATE496301T1
ATE496301T1 AT03809427T AT03809427T ATE496301T1 AT E496301 T1 ATE496301 T1 AT E496301T1 AT 03809427 T AT03809427 T AT 03809427T AT 03809427 T AT03809427 T AT 03809427T AT E496301 T1 ATE496301 T1 AT E496301T1
Authority
AT
Austria
Prior art keywords
cancer diagnosis
cancer
gpc3 detection
gpc3
detection
Prior art date
Application number
AT03809427T
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Yutaka Midorikawa
Kiyotaka Nakano
Iwao Hizumi
Yukio Ito
Susumu Tokita
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Application granted granted Critical
Publication of ATE496301T1 publication Critical patent/ATE496301T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Combined Controls Of Internal Combustion Engines (AREA)
  • Oncology (AREA)
AT03809427T 2002-09-04 2003-09-04 Verfahren zur krebsdiagnose mittels gpc3-nachweis ATE496301T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2002/008997 WO2004023145A1 (ja) 2002-09-04 2002-09-04 Ｇｐｃ3の検出による癌の診断方法
PCT/JP2003/011320 WO2004038420A1 (ja) 2002-09-04 2003-09-04 Gpc3の検出による癌の診断方法

Publications (1)

Publication Number Publication Date
ATE496301T1 true ATE496301T1 (de) 2011-02-15

Family

ID=31972304

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03809427T ATE496301T1 (de) 2002-09-04 2003-09-04 Verfahren zur krebsdiagnose mittels gpc3-nachweis

Country Status (10)

Country Link
US (2) US20060014223A1 (de)
EP (1) EP1548442B1 (de)
JP (1) JP4283227B2 (de)
KR (1) KR101043921B1 (de)
CN (1) CN100554964C (de)
AT (1) ATE496301T1 (de)
AU (2) AU2002330482A1 (de)
CA (1) CA2497418C (de)
DE (1) DE60335813D1 (de)
WO (2) WO2004023145A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022597A1 (ja) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
SI1674111T1 (sl) * 2004-07-09 2011-02-28 Chugai Pharmaceutical Co Ltd Protitelo proti glipikanu 3
JP4733042B2 (ja) 2004-08-24 2011-07-27 中外製薬株式会社 抗グリピカン３抗体を用いたアジュバント療法
US20080003623A1 (en) * 2004-10-05 2008-01-03 Atsushi Nakajima Monitoring Agent for Seriousness of Hepatitis
AU2005297772B2 (en) 2004-10-26 2011-06-23 Chugai Seiyaku Kabushiki Kaisha Anti-glypican 3 antibody having modified sugar chain
ES2373055T3 (es) 2005-08-09 2012-01-31 Oncotherapy Science, Inc. Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno.
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7723043B2 (en) 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
EP2156184B1 (de) * 2007-05-08 2013-11-27 Picobella, LLC Verfahren zur diagnostizierung und behandlung von prostata- und lungenkrebs
ME02345B (me) 2007-07-17 2016-08-31 Squibb & Sons Llc MONOKLONSKA ANTlTELA PROTIV GLIPIKANA-3
US8497355B2 (en) * 2007-09-28 2013-07-30 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3 antibody having improved kinetics in plasma
KR101105428B1 (ko) * 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
WO2013070468A1 (en) * 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
EP3557260B1 (de) 2012-12-21 2022-05-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-gerichtetes arzneimittel, das einem patienten verabreicht wird, der auf die gpc3-gerichtete arzneimitteltherapie reagiert
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
EP3088890B1 (de) 2013-12-24 2020-09-23 Chugai Seiyaku Kabushiki Kaisha Verfahren zur messung von löslichem gpc3-protein
SG11201605784YA (en) * 2014-01-17 2016-08-30 Minomic Internat Ltd Cell surface prostate cancer antigen for diagnosis
JP6827319B2 (ja) 2014-05-08 2021-02-10 中外製薬株式会社 Ｇｐｃ３標的治療剤療法が有効である患者に投与されるｇｐｃ３標的治療剤
WO2015179658A2 (en) * 2014-05-22 2015-11-26 Genentech, Inc. Anti-gpc3 antibodies and immunoconjugates
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
JP7096667B2 (ja) 2015-07-01 2022-07-06 中外製薬株式会社 Ｇｐｃ３標的治療剤が有効である患者に投与されるｇｐｃ３標的治療剤
CN105759051B (zh) * 2016-02-25 2018-12-18 广州科方生物技术股份有限公司 一种磷脂酰肌醇蛋白聚糖-3的定量分析试剂盒及其制备方法
JP6292564B2 (ja) * 2016-03-10 2018-03-14 シスメックス株式会社 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
MX2019008221A (es) 2017-01-10 2019-12-09 Univ Yamaguchi Anticuerpo anti-gpc3.
CN106636108A (zh) * 2017-01-25 2017-05-10 复旦大学附属中山医院 一种特异性结合gpc3的核酸适配体及其应用
CN107085109A (zh) * 2017-05-15 2017-08-22 山东大学深圳研究院 高正电荷绿色荧光蛋白在制备肝癌早期诊断试剂盒中的应用
KR20220083665A (ko) 2019-08-01 2022-06-20 알.피.쉐러 테크놀러지즈 엘엘씨 Gpc3에 특이적인 항체 및 그것의 사용 방법
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
JP7843250B2 (ja) * 2021-01-18 2026-04-09 富士レビオ株式会社 可溶性ｇｐｃ３のイムノアッセイにおける可溶性ｇｐｃ３含有検体の処理方法
IL307927A (en) * 2021-04-23 2023-12-01 Shanghai Henlius Biotech Inc Anti-gpc3 antibodies and methods of use
CN117607440B (zh) * 2023-11-28 2024-05-14 中拓生物有限公司 一种磷脂酰肌醇蛋白聚糖3蛋白测定试剂盒及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644026A (en) 1994-05-03 1997-07-01 La Jolla Cancer Research Foundation Epitaxin, a cell motility factor
US5760000A (en) 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
CA2190041A1 (en) 1995-11-13 1997-05-14 Shinya Inoue Urea derivatives
US5843937A (en) 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
AUPO727097A0 (en) 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
MXPA04011132A (es) * 2002-05-23 2005-08-15 Sunnybrook & Womens College Diagnostico de carcinoma hepatocelular.

Also Published As

Publication number Publication date
HK1079568A1 (zh) 2006-04-07
AU2003261943B2 (en) 2009-07-23
JPWO2004038420A1 (ja) 2006-02-23
AU2002330482A1 (en) 2004-03-29
EP1548442A4 (de) 2007-04-18
AU2003261943A1 (en) 2004-05-13
CN100554964C (zh) 2009-10-28
KR101043921B1 (ko) 2011-06-29
JP4283227B2 (ja) 2009-06-24
US20060014223A1 (en) 2006-01-19
EP1548442A1 (de) 2005-06-29
WO2004038420A1 (ja) 2004-05-06
WO2004023145A1 (ja) 2004-03-18
CA2497418A1 (en) 2004-05-06
CA2497418C (en) 2012-02-07
US20150132782A1 (en) 2015-05-14
DE60335813D1 (de) 2011-03-03
EP1548442B1 (de) 2011-01-19
CN1678911A (zh) 2005-10-05
KR20050057205A (ko) 2005-06-16
US9513292B2 (en) 2016-12-06

Similar Documents

Publication Publication Date Title
ATE496301T1 (de) Verfahren zur krebsdiagnose mittels gpc3-nachweis
DE602006020877D1 (de) Vorrichtung und verfahren zum nachweis eines analyts
ATE425461T1 (de) Diagnose von hepatozellulärem karzinom
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
ATE423972T1 (de) Vorrichtung und verfahren um gleichzeitig verschiedene antikörper und antigene nachzuweisen in klinischen, nahrungsmittel- und umwelt-proben
WO2006089027A3 (en) Lateral flow test kit and method for detecting an analyte
ATE428929T1 (de) Reagens, ausstattung und verfahren zur probenanalyse
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
ATE520983T1 (de) Verfahren zum nachweis eines biomoleküls, dafür verwendeter markierungsfarbstoff und markierungskit
WO2005040759A3 (en) Apparatus and methods for detecting target analyte
ATE416384T1 (de) Verfahren und kit zum quantitativen und/oder qualitativen nachweis von komponenten in einer probe
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
WO2003091695A3 (en) Identification of biomarkers for detecting prostate cancer
ATE555385T1 (de) N1,n12-diacetylspermin als tumormarker
EP1715333A3 (de) Verfahren zur Signalauslesung an einem gassensitiven Feldeffekttransistor
DE69928245D1 (de) Verfahren zur probenentnahme
DE69007898D1 (de) Verfahren zur diagnose der periodontalen krankheit mittels nachweis von alaninaminotransferase.
DE60112949D1 (de) Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes
ATE420358T1 (de) Geräteanordnung und verfahren zum nachweis eines analyten
DE602004026869D1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
ATE437368T1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten
CA2586654A1 (en) Use of asc as a marker for colorectal cancer
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties